1.	Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CDR0000068686, ISIS-3521-CS17, CWRU-040123, ISIS-1501, NCT00017407
2.	Phase II Study of ISIS 3521 in Patients with Refractory or Recurrent High Grade Astrocytomas Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NABTT-9706, JHOC-NABTT-9706
3.	Phase II Randomized Study of ISIS 5132 or ISIS 3521 in Women With Previously Treated Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-3197, NCT00003236, E3197
4.	Phase II Randomized Study of ISIS 3521 and ISIS 5132 in Patients with Hormone Refractory Prostate Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Protocol IDs: CAN-NCIC-IND111, IND111
5.	Phase II Randomized Study of ISIS 3521 and ISIS 5132 for Locally Advanced or Metastatic Colorectal Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Protocol IDs: CAN-NCIC-IND112, IND112
6.	ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: EORTC-16977, ISIS-EORTC-16977, NCT00003989
7.	Phase II Study of ISIS 3521 in Patients With Previously Treated, Low-Grade Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-000808401, ISIS-3521-CS18, NCI-G02-2056